• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stevanato Group brings in upsized IPO worth $453.5M

August 17, 2021 By Sean Whooley

Stevanato GroupStevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares.

The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share.

Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 million after deducting underwriting discounts and commissions, along with other estimated offering expenses. The selling shareholders will receive the remaining net proceeds, according to a news release.

Morgan Stanley, BofA Securities and Jefferies acted as lead book-running managers for the offering. Citigroup, UBS Investment Bank, KeyBanc Capital Markets, Wells Fargo Securities and William Blair acted as book-runners for the offering. Houlihan Lokey served as a financial advisor to the Company.

Stevanato Group develops drug containment, drug delivery and diagnostic technologies. The company has recently been working with Bexson Biomedical on proprietary wearable subcutaneous infusion pump technology. Bexson recently earned a U.S. patent for its BB106 ketamine therapy through the proprietary delivery platform.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: Bexson Biomedical, infusion pump, initial public offering, IPO, shareholders, Stevanato Group, subcutaneous

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS